MCID: HYP014
MIFTS: 50

Hyperuricemia malady

Categories: Metabolic diseases, Rare diseases

Aliases & Classifications for Hyperuricemia

Aliases & Descriptions for Hyperuricemia:

Name: Hyperuricemia 12 52 42 14 69
Uricacidemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1920
MeSH 42 D033461
NCIt 47 C3961
UMLS 69 C0740394

Summaries for Hyperuricemia

Disease Ontology : 12 An acquired metabolic disease that has material basis in an abnormally high level of uric acid in the blood.

MalaCards based summary : Hyperuricemia, also known as uricacidemia, is related to glomerulocystic kidney disease with hyperuricemia and isosthenuria and hyperuricemia, pulmonary hypertension, renal failure, and alkalosis, and has symptoms including cachexia, cyanosis and dyspnea. An important gene associated with Hyperuricemia is UMOD (Uromodulin), and among its related pathways/superpathways are Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds and Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics. The drugs Allopurinol and Colchicine have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and liver, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 71 Hyperuricemia is an abnormally high level of uric acid in the blood. In the pH conditions of body fluid,... more...

Related Diseases for Hyperuricemia

Diseases in the Hyperuricemia family:

Hereditary Hyperuricemia

Diseases related to Hyperuricemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 114)
id Related Disease Score Top Affiliating Genes
1 glomerulocystic kidney disease with hyperuricemia and isosthenuria 33.4 HPRT1 SLC22A12 UMOD
2 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis 12.1
3 autosomal dominant medullary cystic kidney disease with hyperuricemia 12.0
4 autosomal dominant medullary cystic kidney disease without hyperuricemia 12.0
5 hereditary hyperuricemia 11.8
6 deafness hyperuricemia neurologic ataxia 11.8
7 lesch-nyhan syndrome 11.7
8 nephropathy familial with hyperuricemia 11.7
9 nephronophthisis 11.6
10 hyperuricemic nephropathy, familial juvenile 2 11.4
11 hprt-related gout 11.4
12 glycogen storage disease ia 11.0
13 hyperuricemic nephropathy, familial juvenile 1 11.0
14 autosomal dominant tubulointerstitial kidney disease, ren-related 10.9
15 glycogen storage disease ib 10.9
16 familial juvenile hyperuricaemic nephropathy 10.7
17 phosphoribosylpyrophosphate synthetase superactivity 10.7
18 familial juvenile hyperuricemic nephropathy 4 10.7
19 glycogen storage disease ic 10.7
20 gout 10.6
21 kidney disease 10.2
22 persistent hyperplastic primary vitreous, autosomal recessive 10.2 HPRT1 SLC22A12 XDH
23 newborn respiratory distress syndrome 10.2 HPRT1 UMOD XDH
24 posterior foramen magnum meningioma 10.1 HPRT1 XDH
25 spinocerebellar ataxia 5 10.1 HPRT1 SLC22A12 SLC2A9
26 obesity 10.1
27 shaken baby syndrome 10.1 INS REN
28 alopecia-mental retardation syndrome 2 10.1 G6PC INS
29 endotheliitis 10.1
30 calcinosis 10.0 INS REN UMOD
31 meier-gorlin syndrome 4 10.0 HPRT1 XDH
32 chronic myocardial ischemia 10.0 INS REN UMOD
33 anuria 10.0 G6PC INS PFKM
34 uv-sensitive syndrome 9.9 HPRT1 SLC22A12 SLC2A9 UMOD XDH
35 heart disease 9.9
36 posterior uveal melanoma 9.9 APOB HPRT1 INS
37 liver disease 9.9
38 lymphoma 9.9
39 arthritis 9.9
40 atherosclerosis 9.9
41 fatty liver disease 9.9
42 adrenal adenoma 9.8 ADRB3 APOB INS
43 cystinuria 9.8
44 nephrolithiasis 9.8
45 acute myocardial infarction 9.8
46 atrial fibrillation 9.8
47 myocardial infarction 9.8
48 cervix small cell carcinoma 9.8 APOB INS REN
49 hepatitis 9.8
50 leukemia 9.8

Graphical network of the top 20 diseases related to Hyperuricemia:



Diseases related to Hyperuricemia

Symptoms & Phenotypes for Hyperuricemia

UMLS symptoms related to Hyperuricemia:


cachexia, cyanosis, dyspnea, edema, fever, headache, icterus, seizures, signs and symptoms, signs and symptoms, digestive, syncope, vertigo, polydipsia, muscle weakness, hot flushes

MGI Mouse Phenotypes related to Hyperuricemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.1 ABCG2 ADRB3 APOB G6PC HPRT1 INS
2 growth/size/body region MP:0005378 10.07 UMOD XDH ADRB3 APOB G6PC HPRT1
3 behavior/neurological MP:0005386 10.06 PFKM REN SLC22A12 SLC2A9 UMOD ADRB3
4 adipose tissue MP:0005375 9.91 ABCG2 ADRB3 INS SLC2A9 UMOD XDH
5 immune system MP:0005387 9.91 ABCG2 APOB HPRT1 INS PFKM REN
6 liver/biliary system MP:0005370 9.63 ABCG2 APOB G6PC HPRT1 INS SLC2A9
7 muscle MP:0005369 9.43 APOB HPRT1 INS PFKM REN XDH
8 renal/urinary system MP:0005367 9.28 SLC2A9 UMOD XDH ABCG2 G6PC HPRT1

Drugs & Therapeutics for Hyperuricemia

Drugs for Hyperuricemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Allopurinol Approved Phase 4,Phase 3,Phase 2,Early Phase 1 315-30-0 2094
2
Colchicine Approved Phase 4,Phase 2 64-86-8 6167 2833
3
Probenecid Approved Phase 4,Phase 2 57-66-9 4911
4
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
5
Febuxostat Approved Phase 4,Phase 3,Phase 2,Phase 1 144060-53-7 134018
6
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
7
Rasburicase Approved, Investigational Phase 4,Phase 3,Phase 2 134774-45-1
8
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
9
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
10
Canagliflozin Approved Phase 4 842133-18-0
11
Uric Acid Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 69-93-2 1175
12 insulin Phase 4,Phase 3
13 Protective Agents Phase 4,Phase 3,Phase 2,Early Phase 1
14 Insulin, Globin Zinc Phase 4,Phase 3
15 Antimetabolites Phase 4,Phase 3,Phase 2,Early Phase 1
16 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Antioxidants Phase 4,Phase 3,Phase 2,Early Phase 1
18
Benzbromarone Phase 4,Phase 3,Phase 1,Phase 2 3562-84-3 2333
19
Angiotensin II Phase 4 68521-88-0, 11128-99-7 65143 172198
20
Olmesartan medoxomil Phase 4 144689-63-4 130881
21 Analgesics Phase 4,Phase 2
22 glucocorticoids Phase 4,Phase 2,Phase 3
23 Analgesics, Non-Narcotic Phase 4,Phase 2
24 Hormone Antagonists Phase 4,Phase 2,Phase 3
25 Diacetylrhein Phase 4
26 Hormones Phase 4,Phase 2,Phase 3
27 Peripheral Nervous System Agents Phase 4,Phase 2
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
29 Angiotensin II Type 1 Receptor Blockers Phase 4
30 Angiotensin Receptor Antagonists Phase 4
31 Angiotensinogen Phase 4
32 Hypoglycemic Agents Phase 4
33 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
34 Antihypertensive Agents Phase 4,Phase 3,Phase 2
35 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
36 Renal Agents Phase 4,Phase 3,Phase 1,Phase 2
37 Antimitotic Agents Phase 4,Phase 2
38 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
39 Anti-Infective Agents Phase 4
40 Antiparasitic Agents Phase 4
41 Antiprotozoal Agents Phase 4
42
Proton pump inhibitors Phase 4
43 Gastrointestinal Agents Phase 4
44 Cyclooxygenase Inhibitors Phase 4
45 Antacids Phase 4
46 Anti-Ulcer Agents Phase 4
47
Procyanidin Nutraceutical Phase 4 4852-22-6 147299
48 Anthocyanidin Nutraceutical Phase 4
49 Proanthocyanidin Nutraceutical Phase 4
50
Chlorthalidone Approved Phase 3 77-36-1 2732

Interventional clinical trials:

(show top 50) (show all 123)
id Name Status NCT ID Phase
1 Prednisone for Heart Failure Patients With Hyperuricemia Completed NCT00919243 Phase 4
2 Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome Completed NCT00563771 Phase 4
3 Rasburicase in Tumor Lysis Syndrome Completed NCT00302653 Phase 4
4 Treatment of Hyperuricemia in Patients With Heart Failure Completed NCT00422318 Phase 4
5 Zurig (Febuxostat) 40mg Efficacy and Safety Trial Completed NCT02600780 Phase 4
6 Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome Completed NCT01654276 Phase 4
7 Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Completed NCT00230217 Phase 4
8 Allopurinol in Chronic Heart Failure Completed NCT00997542 Phase 4
9 Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers Completed NCT01907373 Phase 4
10 Allopurinol Outcome Study Completed NCT01391325 Phase 4
11 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
12 Fasturtec TLS Treatment / Prophylysis Completed NCT00651911 Phase 4
13 Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels Completed NCT02060552 Phase 4
14 Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines Recruiting NCT02797028 Phase 4
15 The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics Recruiting NCT02956278 Phase 4
16 Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout Active, not recruiting NCT02500641 Phase 4
17 Pharmacogenetics of SGLT2 Inhibitors Enrolling by invitation NCT02462421 Phase 4
18 the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia Not yet recruiting NCT02279342 Phase 4
19 Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia Completed NCT00921375 Phase 3
20 Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome Completed NCT00230178 Phase 3
21 Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma Completed NCT00199043 Phase 3
22 Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout Completed NCT00325195 Phase 3
23 Efficacy and Safety of Oral Febuxostat in Participants With Gout Completed NCT00430248 Phase 3
24 Uric Acid and Hypertension in African Americans Completed NCT00241839 Phase 3
25 Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout Completed NCT01356498 Phase 3
26 Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 Completed NCT00175019 Phase 3
27 Prednisone for Heart Failure Patients With Hyperuricemia Recruiting NCT02129764 Phase 2, Phase 3
28 Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout Recruiting NCT03100318 Phase 3
29 Study of FYU-981 in Hyperuricemia With or Without Gout Recruiting NCT03006445 Phase 3
30 Long-term Prednisone Use for End-stage Heart Failure Recruiting NCT02282683 Phase 2, Phase 3
31 UAB Center of Research Translation (CORT) Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood Pressure Recruiting NCT02038179 Phase 2, Phase 3
32 The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients Recruiting NCT02563405 Phase 2, Phase 3
33 Role of Allopurinol on Oxidative Stress and Mitochondrial Alterations in Skeletal Muscle of Diabetic Patients Recruiting NCT02533648 Phase 3
34 Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities Active, not recruiting NCT01101035 Phase 3
35 Rasburicase (Fasturtec) Registration Trial Terminated NCT00607152 Phase 3
36 Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout Unknown status NCT01519687 Phase 2
37 A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product. Unknown status NCT00208000 Phase 2
38 Hyperuricemia on Hypertension and Metabolic Syndrome Completed NCT01157936 Phase 2
39 Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia Completed NCT00995618 Phase 2
40 Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia Completed NCT01052987 Phase 2
41 Study of FYU-981 in Hyperuricemia With or Without Gout Completed NCT02344862 Phase 2
42 Study of FYU-981 in Hyperuricemia With or Without Gout Completed NCT02416167 Phase 2
43 Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia Completed NCT02078219 Phase 2
44 A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients Completed NCT02317861 Phase 1, Phase 2
45 Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout Completed NCT01336686 Phase 2
46 Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients Completed NCT01416402 Phase 2
47 A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout Completed NCT00741442 Phase 2
48 Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout Completed NCT02252835 Phase 2
49 Rasburicase for Hyperuricemia Completed NCT00290992 Phase 2
50 Phase II Exploratory Clinical Study of KUX-1151 Completed NCT02190786 Phase 2

Search NIH Clinical Center for Hyperuricemia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: hyperuricemia

Genetic Tests for Hyperuricemia

Anatomical Context for Hyperuricemia

MalaCards organs/tissues related to Hyperuricemia:

39
Kidney, Heart, Liver, Endothelial, Bone, Bone Marrow, Thyroid

Publications for Hyperuricemia

Articles related to Hyperuricemia:

(show top 50) (show all 681)
id Title Authors Year
1
Acupuncture for serum uric acid in patients with asymptomatic hyperuricemia: A randomized, double-blind, placebo-controlled trial. ( 28087178 )
2017
2
Incidence and Simple Prediction Model of Hyperuricemia for Urban Han Chinese Adults: A Prospective Cohort Study. ( 28085072 )
2017
3
Development of Nephrolithiasis in Asymptomatic Hyperuricemia: A Cohort Study. ( 28410765 )
2017
4
(E)-2-(4-bromophenyl)-1-(2, 4-dihydroxyphenyl)ethanone oxime is a potential therapeutic agent for treatment of hyperuricemia through its dual inhibitory effects on XOD and URAT1. ( 27951420 )
2017
5
Asymptomatic hyperuricemia is a strong risk factor for resistant hypertension in elderly subjects from general population. ( 28027534 )
2017
6
Assessment of subclinical left ventricular changes in essential hypertensive patients with hyperuricemia: A three-dimensional speckle-tracking echocardiography study. ( 28072551 )
2017
7
Association between plasma proANP and hyperuricemia in Chinese Han women: a cross-sectional study. ( 28076299 )
2017
8
Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia. ( 27211368 )
2016
9
Comparison of the Renoprotective Effect of Febuxostat for the Treatment of Hyperuricemia between Patients with and without Type 2 Diabetes Mellitus: A Retrospective Observational Study. ( 27853065 )
2016
10
Hyperuricemia is associated with the increase of insulin release in non-obese subjects with normal glucose tolerance. ( 27045210 )
2016
11
Uric acid lowering effect of Tibetan Medicine RuPeng15 powder in animal models of hyperuricemia. ( 27400475 )
2016
12
Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. ( 27605442 )
2016
13
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview. ( 27423335 )
2016
14
Spatiotemporal gait parameters and plantar pressure distribution during barefoot walking in people with gout and asymptomatic hyperuricemia: comparison with healthy individuals with normal serum urate concentrations. ( 27134680 )
2016
15
Hyperuricemia is associated with increased hospitalization risk and healthcare costs: Evidence from an administrative database in Italy. ( 27555289 )
2016
16
The Relation of Moderate Alcohol Consumption to Hyperuricemia in a Rural General Population. ( 27447659 )
2016
17
Astilbin improves potassium oxonate-induced hyperuricemia and kidney injury through regulating oxidative stress and inflammation response in mice. ( 27522260 )
2016
18
Hyperuricemia in Tendons. ( 27535254 )
2016
19
In Reply to 'Febuxostat for Asymptomatic Hyperuricemia in CKD' and 'Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia'. ( 27211369 )
2016
20
Hyperuricemia and uncontrolled hypertension in treated hypertensive patients: K-MetS Study. ( 27428212 )
2016
21
Lesinurad (Zurampic) for gout-associated hyperuricemia. ( 27849193 )
2016
22
Hyperuricemia and Cardiovascular Disease in Patients with Hypertension. ( 27024979 )
2016
23
Natural Products Improving Hyperuricemia with Hepatorenal Dual Effects. ( 27847526 )
2016
24
Hyperuricemia: A causal player or a bystander linking inflammatory signaling and atrial fibrillation? ( 27993379 )
2016
25
Atherogenic Index of Plasma Predicts Hyperuricemia in Rural Population: A Cross-Sectional Study from Northeast China. ( 27598187 )
2016
26
Hyperuricemia, the kidneys, and the spectrum of associated diseases: a narrative review. ( 27470664 )
2016
27
Total saponins from dioscorea septemloba thunb reduce serum uric acid levels in rats with hyperuricemia through OATP1A1 up-regulation. ( 27072969 )
2016
28
Prediction of Therapeutic Effect of Rasburicase on Hyperuricemia Associated with Chemotherapy Based on Theoretical Model. ( 27150142 )
2016
29
Beyond Joints: a Review of Ocular Abnormalities in Gout and Hyperuricemia. ( 27138165 )
2016
30
Hyperuricemia as a risk factor for cardiovascular disease: clinical review. ( 27922586 )
2016
31
Hyperuricemia, Cardiovascular Disease, and Hypertension. ( 27195245 )
2016
32
Association between high-sensitivity C-reactive protein and hyperuricemia. ( 26862048 )
2016
33
Association between anthropometric indices and hyperuricemia in rural area of China: Methodological issues. ( 28029414 )
2016
34
Prognostic Significance of Hyperuricemia in Patients With Acute Heart Failure. ( 27040576 )
2016
35
Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2. ( 27571712 )
2016
36
Hyperuricemia is an independent competing risk factor for atrial fibrillation. ( 27871785 )
2016
37
Metabolomic profiles delineate the effect of Sanmiao wan on hyperuricemia in rats. ( 27450803 )
2016
38
Hyperuricemia Is an Independent Risk Factor for Erectile Dysfunction. ( 27209181 )
2016
39
Difference in the action mechanism of radon inhalation and radon hot spring water drinking in suppression of hyperuricemia in mice. ( 27021217 )
2016
40
Metabolically healthy obesity also has risk for hyperuricemia among Chinese general population: A cross-sectional study. ( 27061989 )
2016
41
Hyperuricemia Protects Against Low Bone Mineral Density, Osteoporosis and Fractures: A Systematic Review And Meta-Analysis. ( 27636234 )
2016
42
Hyperuricemia as a potential risk factor for type 2 diabetes and diabetic nephropathy. ( 28001176 )
2016
43
The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout. ( 27980008 )
2016
44
Catalysis and Structure of Zebrafish Urate Oxidase Provide Insights into the Origin of Hyperuricemia in Hominoids. ( 27922051 )
2016
45
Assessment of myocardial performance index in hypertensive patients with or without hyperuricemia. ( 27160174 )
2016
46
How can machine-learning methods assist in virtual screening for hyperuricemia? A healthcare machine-learning approach. ( 27658886 )
2016
47
Ultrasonography in the diagnosis of asymptomatic hyperuricemia and gout. ( 27906639 )
2016
48
Hyperuricemia in systemic lupus erythematosus: is it associated with the neuropsychiatric manifestations of the disease? ( 27914592 )
2016
49
Febuxostat for Asymptomatic Hyperuricemia in CKD. ( 27211367 )
2016
50
Hyperferritinemia increases the risk of hyperuricemia in HFE-hereditary hemochromatosis. ( 27659401 )
2016

Variations for Hyperuricemia

Expression for Hyperuricemia

Search GEO for disease gene expression data for Hyperuricemia.

Pathways for Hyperuricemia

GO Terms for Hyperuricemia

Cellular components related to Hyperuricemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.1 ABCG2 PFKM SLC17A3 SLC22A12 SLC2A9 UMOD
2 endosome lumen GO:0031904 8.96 APOB INS

Biological processes related to Hyperuricemia according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.8 ABCG2 SLC17A1 SLC17A3 SLC22A12 SLC2A9
2 glucose homeostasis GO:0042593 9.61 G6PC INS PFKM
3 cholesterol efflux GO:0033344 9.52 ABCG2 APOB
4 organic anion transport GO:0015711 9.51 SLC17A3 SLC2A9
5 drug transmembrane transport GO:0006855 9.49 ABCG2 SLC17A3
6 glycogen catabolic process GO:0005980 9.48 G6PC PFKM
7 phosphate ion transmembrane transport GO:0035435 9.46 SLC17A1 SLC17A3
8 phosphate ion transport GO:0006817 9.37 SLC17A1 SLC17A3
9 glucose transport GO:0015758 9.33 G6PC INS SLC2A9
10 urate transport GO:0015747 9.32 SLC17A3 SLC22A12
11 glucose-6-phosphate transport GO:0015760 9.26 G6PC SLC17A3
12 organic acid transmembrane transport GO:1903825 9.13 SLC17A3 SLC22A12 SLC2A9
13 urate metabolic process GO:0046415 9.1 ABCG2 G6PC SLC17A1 SLC17A3 SLC22A12 SLC2A9

Molecular functions related to Hyperuricemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.72 ABCG2 ADRB3 HPRT1 PFKM XDH
2 cholesterol transporter activity GO:0017127 9.26 ABCG2 APOB
3 insulin-like growth factor receptor binding GO:0005159 9.16 INS REN
4 sodium:phosphate symporter activity GO:0005436 8.96 SLC17A1 SLC17A3
5 urate transmembrane transporter activity GO:0015143 8.8 SLC17A3 SLC22A12 SLC2A9

Sources for Hyperuricemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....